Oracle Health Sciences InForm Advanced Molecular Analytics Enables Life Sciences Organizations to Incorporate Genomic Data Into Clinical R&D for Targeted, Biomarker-Driven Clinical Trials
Solution Extends the Capabilities of Oracle Health Sciences InForm GTM to Effectively Collect, Store and Analyze Genomic Data
BOSTON, MA, Mar 25, 2014 (Marketwired via COMTEX) -- ORACLE INDUSTRY CONNECT -- Oracle ORCL +0.84%
News Summary Biomarkers are becoming a key component of clinical trial design, enabling researchers to rapidly find subjects with similar clinical and omics characteristics. Oracle Health Sciences InForm Advanced Molecular Analytics is one of the first commercially available cloud-delivery solutions to incorporate genomics into the clinical data capture and management process. Integrated with Oracle Health Sciences InForm GTM, the solution enables clinical researchers to effectively capture, aggregate and analyze molecular data along with clinical data to provide the information needed to identify new predictive biomarkers. The solution facilitates the stratification of patients into target populations of responders to accelerate trials and improve drug and therapeutic outcomes.
-- Oracle Health Sciences today announced Oracle Health Sciences InForm
Advanced Molecular Analytics. Integrated with Oracle Health Sciences
InForm GTM, the solution enables clinical trial managers to
systematically and effectively collect, store and analyze genomic data
captured in a clinical trial.
-- The new capabilities of Oracle Health Sciences InForm Advanced
Molecular Analytics help life sciences organizations to stratify
patients and reduce research and development costs by leveraging
targeted drug development approaches and decreasing study size and
length. The solution also helps researchers identify new indications
and therapies through post-trial, cross-study analysis with molecular
-- Collecting biomarker data is typically a difficult manual effort,
aggregating data scattered across spreadsheets, file systems and
siloed transaction systems. With Oracle Health Sciences InForm
Advanced Molecular Analytics, researchers have consolidated access to
both clinical and genomic data for numerous purposes, such as
submission or the design of more exploratory translational research
studies, including those that can generate petabytes of data from
thousands of whole genome sequences.
-- Life sciences organizations can gain a single, integrated view of
genomic, genetic and clinical data, enabling clinical researchers to
identify and validate new targets. The solution supports multiple
omics modalities and targeted gene panels and can scale to handle
hundreds of thousands of whole genomes.
-- Clinical researchers can study patient genomic profiles, analyze
differences and compare molecular data against common large public
domain data sets, such as The Cancer Genome Atlas -- streamlining
analysis and increasing statistical power.
-- The Oracle Health Sciences InForm Advanced Molecular Analytics
solution leverages proven technology from Oracle Health Sciences
Translational Research Center to deliver one of the first commercially
available "molecular-aware" clinical data capture and management
-- Oracle Health Sciences InForm Advanced Molecular Analytics is deployed
as software-as-a-service (SaaS) and is fully integrated with the
Oracle Health Sciences InForm Cloud Service. As a comprehensive and
commercially available SaaS solution, life sciences organizations
avoid the cost and time associated with building and maintaining
-- "As clinical trial design advances and becomes more targeted, new
dynamics emerge in clinical research and development, such as the
increasing need to quickly and reliably identify and validate
biomarker hypotheses," said Mukhtar Ahmed, global vice president of
product strategy, Oracle Health Sciences. "Oracle Health Sciences
InForm Advanced Molecular Analytics expands the industry leading
capabilities of Oracle Health Sciences InForm with new genomic
management and analysis capabilities to facilitate more targeted trial
design and drug development."
-- "The adoption of our translational research platform in the healthcare
sector by top-tier academic medical centers demonstrates that our
genomics solutions have been tried, tested and shown to scale at an
enterprise level," said Jonathan Sheldon, PhD, global vice president,
Oracle Health Sciences. "With the release of Oracle Health Sciences
InForm Advance Molecular Analytics, we are delivering a
'biomarker-aware' clinical platform to help enable sponsors to design
more targeted genomics studies."
-- Oracle in Health Sciences
-- Oracle Health Sciences InForm
-- Oracle Health Sciences Translational Research Center
-- Oracle Health Sciences Cohort Explorer
-- Oracle Health Sciences Omics Data Bank
-- Follow Oracle Health Sciences on Twitter
-- Join the Oracle Health Sciences Community on Facebook
-- Oracle Health Sciences on YouTube
About Oracle Health Sciences At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health. We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. For more information, visit http://www.oracle.com/us/industries/health-sciences/index.html .
About Oracle Industry Connect Oracle Industry Connect, taking place in Boston March 25-26, 2014, brings industry leaders together to share deep domain expertise, insights and industry-specific best practices. This leadership event features customer-led content including visionary keynotes, executive-level networking and in-depth case studies designed to help organizations meet industry-specific challenges. For more information, please visit www.oracleindustryconnect.com .
Trademarks Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Disclaimer The above is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle's products remains at the sole discretion of Oracle Corporation.
O'Keeffe & Company
SOURCE: Oracle Corporation